CuraLase clinics have administered over 100,000 treatments to over 8,000 patients from 44 states and 31 countries, establishing an international reputation for exceptional patient care. Achieving over a 90% success rate, CuraLase offers a non-invasive treatment option to individuals with pain. CuraLase delivers a pathway for patients to “get their quality of life back.”
The CuraLase History
Since its founding in 2005, CuraLase has been an innovator in non-invasive Photon Therapy treatment for a multitude of painful conditions. Roger Porter, inventor and engineer, was seeking an alternative treatment for a family member’s excruciating pain from rheumatoid arthritis when he met Frank G. McArthur, MD. Dr. McArthur had previously been the Medical Director of over 3,000 rehabilitation hospitals (Health South). Working together, Porter and McArthur researched and developed an innovative device and treatment protocols. In December 2005, the CuraLase device was FDA cleared as a risk free treatment for pain. The FDA rated the CL1000 with the safest classification awarded to any treatment modality. The first clinic opened in March 2006 in Myrtle Beach, South Carolina. Porter and a team of seven physicians refined the treatment protocols and developed new treatment protocols with greater than a 90% success rate.
CuraLase was awarded FDA clearance in 2005.
Harvard clinical trial proves PBM activates stem cells to regenerate tissue
Harvard School of Engineering and Applied Sciences (SEAS)
David J. Mooney, Praveen Arany, Ph.D.,
Harvard’s groundbreaking new research in the use of PBM to stimulate stem cells to regrow tissue is generating interest and excitement throughout the medical community.
Stem cells stimulated by PBM has “profound beneficial effects”.
The George S. Wise Faculty of Life Sciences, Tel-Aviv University, Tel-Aviv 69978, Israel
Tuby H, Maltz L, Oron U.
The application of PBM offers a novel approach to induce BM-derived MSCs, which are consequently recruited from the circulation to the infarcted heart and markedly attenuate the scarring process post-MI.
PBM to the Bone Marrow Reduces Scarring and Improves Heart Function Post-Acute Myocardial Infarction.
1 Cardiology Division, Assaf Harofeh Medical Center , Zerifin, Israel .
2 Sackler School of Medicine, Tel Aviv University , Tel Aviv, Israel .
3 Deprtment of Zoology, Faculty of Life Sciences, Tel-Aviv University , Tel Aviv, Israel.
4 Preclinical Unit, Assaf Harofeh Medical Center , Zerifin, Israel.
5 Department of Radiology, Assaf Harofeh Medical Center , Zerifin, Israel.
6 School of Veterinary Medicine, Hebrew University , Jerusalem, Israel.
7 Heart Institute, Kaplan Medical Center , Rehovot, Israel .
8 Cardiac MRI Unit, Shiba Medical Center , Ramat-Gan, Israel.
Blatt A, Elbaz-Greener GA, Tuby H, Maltz L, Siman-Tov Y, Ben-Aharon G, Copel L, Eisenberg I, Efrati S, Jonas M, Vered Z, Tal S, Goitein O, Oron U.
PBM application to BM for MI caused a significant reduction in scarring, enhanced angiogenesis and functional improvement both in the acute and long term phase post-MI.
Induction of Autologous Bone-Marrow Stem Cells by PBM Has Beneficial Effects on the Kidneys Post-Ischemia-Reperfusion Injury.
The George S. Wise Faculty of Life Sciences, Tel-Aviv University, Tel-Aviv, Israel.
Hana Tuby, Lidya Maltz, Uri Oron
Stem cells stimulated with PBM can do more than just reduce scar tissue in hearts after heart attack. Additional studies show that stem cells can rejuvenate liver and kidney, and even migrate from bone marrow to the ischemia-reperfusion injury in the kidney resulting in improved organ function. Is this proof-of-concept for an underlying mechanism by which laser therapy, used to relieve pain in the lower back, knees or joints, could be repairing bone or muscle tissue?